Thioredoxin is a metabolic rheostat controlling regulatory B cells

9Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Metabolic programming is important for B cell fate, but the bioenergetic requirement for regulatory B (Breg) cell differentiation and function is unknown. Here we show that Breg cell differentiation, unlike non-Breg cells, relies on mitochondrial electron transport and homeostatic levels of reactive oxygen species (ROS). Single-cell RNA sequencing analysis revealed that TXN, encoding the metabolic redox protein thioredoxin (Trx), is highly expressed by Breg cells, unlike Trx inhibitor TXNIP which was downregulated. Pharmacological inhibition or gene silencing of TXN resulted in mitochondrial membrane depolarization and increased ROS levels, selectively suppressing Breg cell differentiation and function while favoring pro-inflammatory B cell differentiation. Patients with systemic lupus erythematosus (SLE), characterized by Breg cell deficiencies, present with B cell mitochondrial membrane depolarization, elevated ROS and fewer Trx+ B cells. Exogenous Trx stimulation restored Breg cells and mitochondrial membrane polarization in SLE B cells to healthy B cell levels, indicating Trx insufficiency underlies Breg cell impairment in patients with SLE.

Cite

CITATION STYLE

APA

Bradford, H. F., McDonnell, T. C. R., Stewart, A., Skelton, A., Ng, J., Baig, Z., … Mauri, C. (2024). Thioredoxin is a metabolic rheostat controlling regulatory B cells. Nature Immunology, 25(5), 873–885. https://doi.org/10.1038/s41590-024-01798-w

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free